JANUARY 28, 2012

Browse Categories

Contribute to UroToday

Contribute to UroToday

Be a part of the published community of UroToday and promote awareness among your colleagues.

If you are interested in writing for UroToday Contact Us

editors@urotoday.com

Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
Urotoday Exclusives

BERKELEY, CA (UroToday.com) - An Optimistic Take on Recent Onset BPS/IC  

Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
CAUTI Challenge

CAUTI CHALLENGE TODAY (TM) is a part of your Urology Insights newsletter subscription. Access the latest commentary from CAUTI Expert Diane K. Newman, recent publications and experiences from those in the CAUTI treatment community.
Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
UIJ

UroToday International Journal is a peer-reviewed, online publication featuring many types of articles about clinical urology and basic research in urology.
No Cost
There is no charge to submit, or publish an article in the UroToday International Journal. Additionally, there are no charges for color figures.
.....
Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board

Exclusive Headlines

Beyond the Abstract - Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer, by Chantal Mengus, PhD, et al.

BERKELEY, CA (UroToday.com) - Prostate cancer (PCA) is the second leading cause of cancer-related death in men with a death rate reaching 26.7% for 2001-2005 in the United States.[1]

see full text
Beyond the Abstract - Optimization of PSA screening policies: A comparison of the patient and societal perspectives, by Jingyu Zhang, PhD

BERKELEY, CA (UroToday.com) - While there is increasing concern regarding over-diagnosis, prostate cancer mortality rates have fallen dramatically since the introduction of the PSA test.

see full text
Beyond the Abstract - The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer, by Mikkel Bandak

BERKELEY, CA (UroToday.com) - Orchiectomy, followed by active surveillance, is becoming the preferred treatment option for patients with stage I testicular cancer in all large centers in the world.

see full text
Beyond the Abstract - Multicenter study identified molecular blood-born protein signatures for Wilms tumor, by Jana Schmitt

BERKELEY, CA (UroToday.com) - Wilms Tumor (WT) is a very common renal tumor in childhood with more than 75% of cases diagnosed before the age of 5 years.

see full text

BJU Int Mini Reviews

UroToday News

Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer - Abstract

PURPOSE: We report a Phase II trial assessing the acute and late toxicities of intensity-modulated radiation therapy (IMRT), long-term androgen suppression (LTAS), and bevacizumab in patients with high-risk localized prostate cancer.

see full text
Reirradiation of paraaortic lymph node metastasis by brachytherapy with hyaluronate injection via paravertebral approach: With DVH comparison to IMRT - Abstract

INTRODUCTION: To safely irradiate retroperitoneal targets as paraaortic lymph node by separating abdominal at-risk organs from the target during irradiation, we created a percutaneous paravertebral approach of high-dose-rate brachytherapy with hyaluronate gel injection (HGI).

see full text
Evaluating the PCPT risk calculator in ten international biopsy cohorts: Results from the Prostate Biopsy Collaborative Group - Abstract

OBJECTIVES: To evaluate the discrimination, calibration, and net benefit performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) across five European randomized study of screening for prostate cancer (ERSPC), 1 United Kingdom, 1 Austrian, and 3 US biopsy

see full text

Share |